Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Can we predict who will benefit most from biologics in severe asthma? A post-hoc analysis of two phase 3 trials

Fig. 2

Lorenz curve for the heterogeneity of treatment benefit comparing 75 mg mepolizumab versus placebo in severe asthma. Left panel, predicted reduction in rate of severe exacerbations in 365 days of follow up. Right panel, predicted reduction in ACQ5 scores in 365 days of follow up. The Gini Index captures the level of inequality in predicted treatment benefit

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us